Previous Close | 29.34 |
Open | 29.36 |
Bid | 29.12 x 4000 |
Ask | 29.10 x 2200 |
Day's Range | 28.95 - 29.44 |
52 Week Range | 25.20 - 33.92 |
Volume | |
Avg. Volume | 31,953,589 |
Market Cap | 165.241B |
Beta (5Y Monthly) | 0.62 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.46 |
Earnings Date | Oct 29, 2024 |
Forward Dividend & Yield | 1.68 (5.76%) |
Ex-Dividend Date | Nov 08, 2024 |
1y Target Est | 33.34 |
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
Novavax stock remains volatile. After hitting a two-year high in June on enthusiasm for its updated Covid vaccine, shares have pulled back.
NEW YORK, October 11, 2024--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency) without factor VIII (FVIII) inhibitors, or hemophilia B (congenital factor IX deficiency) without factor IX (FIX) inhibitors.